Protecting more children from meningitis by developing a new MenB vaccine | Children's Charity

Protecting more children from meningitis by developing a new MenB vaccine

This research was completed on 31 August 2017

Published on 15 February 2014

Meningococcal disease is a serious illness that strikes with alarming speed, causing meningitis and blood poisoning and killing one in 10 of those affected.1,2 Those who survive can be left with lifelong disabilities. Babies and young children under four are most at risk, although people of all ages are susceptible.1,3 Vaccines are already available, but they don’t protect against all of the bacteria that cause meningococcal disease. Professor Christoph Tang at the University of Oxford is hoping to broaden protection by developing a new vaccine – with the aim of both sparing more children from disability and saving more lives.

How are children’s lives affected now?

“Meningococcal disease is devastating,” says Professor Tang “Children with this disease can rapidly become seriously ill, developing blood poisoning or the severe form of meningitis. Early symptoms include fever, rash, a headache, vomiting and crying.”

Over half of those who develop meningococcal disease in the UK are babies or children under four years old.3 The disease can be deadly and can dramatically change the lives of those who survive.

“Meningococcal disease still kills around 10 per cent of those affected, often within just 24 to 48 hours.” says Professor Tang.1 “Children who survive can suffer long-term consequences, including learning disabilities, seizures and deafness. Some need to have fingers, toes, or even an arm or a leg amputated.”4

Vaccines are already available that can protect us against meningococcal disease, but they don’t work against every bacterium that causes this devastating illness, leaving us vulnerable to life-threatening infections.

How could this research help?

“We are in the laboratory stages of designing a new vaccine for meningococcal disease,” explains Professor Tang. “Over 90 per cent of cases of this disease in the UK result from infection with a bacterium known as MenB, so we are focusing on fighting that bacterium.”1

The new vaccine will work by teaching the immune system to recognise certain proteins that appear on MenB’s surface. As the appearance of these proteins can vary from one bacterium to another, the challenge is to develop vaccines that teach the immune system to recognise as many different MenB bacteria as possible.

“By the end of this project, we hope to have a new vaccine against MenB to move forward into clinical trials in children and young adults,” explains Professor Tang.

Men B kills more children under five than any other infectious disease in the UK.5,6 The need to protect more children through better vaccination is high.

Project LeaderProfessor C M Tang MB ChB MRCP PhD FMedSci
LocationSir William Dunn School of Pathology, University of Oxford
Duration3 years
Grant awarded15 November 2013
Start date1 September 2014
End date31 August 2017
Grant amount£199,991.00
Grant codeGN2205

We do not provide medical advice. If you would like more information about a condition or would like to talk to someone about your health, contact NHS Choices or speak to your GP. Please see our useful links page for some links to health information, organisations we are working with and other useful organisations. We hope you will find these useful. We are not responsible for the content of any of these sites.

References

1. Public Health England. Meningococcal infection factsheet. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733822509 Website accessed 11 December 2013.

2. http://www.meningitis.com/ Website accessed 3 January 2014.

3. Public Health England. Laboratory confirmed cases of all invasive meningococcal disease by serogroup, age and epidemiological year, England and Wales, 2000-01 to 2009-10. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1234859710351 Website accessed 11 December 2013.

4. Viner RM et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012; 11 (9): 774-83.

5. Meningitis Research Foundation. MenB vaccine to be available in the UK privately. http://www.meningitis.org/news-media/bexsero Website accessed 11 December 2013.

6. Office for National Statistics. Mortality statistics: Deaths registered in 2010 (Series DR) Table 5.1 http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=... Website accessed 11 December 2013.

Help us spread the word